• Lantheus Holdings (NasdaqGM:LNTH) plans to present new clinical data for LNTH-2403, an LRRC15-targeted radiopharmaceutical, at the 2026 ASCO Annual Meeting.
• The company will also share real-world data on piflufolastat F 18 imaging use in early-stage prostate cancer at the same conference.
• These updates provide fresh detail on both Lantheus's osteosarcoma pipeline and the adoption of its approved prostate cancer imaging agent.

Lantheus focuses on radiopharmaceuticals and imaging agents used in cancer diagnosis and treatment. The upcoming ASCO presentations highlight LNTH-2403 in osteosarcoma and show how piflufolastat F 18 is being used in routine prostate cancer care. These are both areas of interest for investors tracking oncology tools and diagnostics.

For investors, ASCO often serves as a checkpoint on how pipelines and approved products are progressing. The new data may influence how the market views NasdaqGM:LNTH in terms of product breadth, research progress, and its position within radiopharmaceuticals and prostate cancer imaging.

Stay updated on the most important news stories for Lantheus Holdings by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Lantheus Holdings.

Investor Checklist

Quick Assessment

• ⚖️ Price vs Analyst Target: At US$99.62, the stock sits around 5% below the US$105.23 analyst consensus, within the typical 10% band.
• ✅ Simply Wall St Valuation: Shares are described as trading at 47.9% below an estimated fair value, which flags a sizeable valuation gap.
• ✅ Recent Momentum: A 19.2% return over 30 days shows investors have recently responded positively to the story.

There is only one way to know the right time to buy, sell or hold Lantheus Holdings. Head to Simply Wall St's company report for the latest analysis of Lantheus Holdings's Fair Value.

Key Considerations

• 📊 New LNTH-2403 and piflufolastat F 18 data at ASCO focuses attention on both pipeline depth and real world product use.
• 📊 Watch how the share price behaves around ASCO, changes in analyst targets, and any updates to revenue or earnings expectations tied to these assets.
• ⚠️ Simply Wall St flags one minor risk linked to large one off items in results, so consider the quality and consistency of earnings when reviewing this news.

Dig Deeper

For the full picture including more risks and rewards, check out the complete Lantheus Holdings analysis. Alternatively, you can check out the community page for Lantheus Holdings to see how other investors believe this latest news will impact the company's narrative.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.